MD Anderson

Technology Modalities

ROR1 Emerges in Mantle-Cell Relapse After CD19 CAR-T

A peer-reviewed Leukemia letter reports increased ROR1 expression in mantle-cell lymphoma specimens after CD19 CAR-T relapse and shows that experimental ROR1/CD3 T-cell engagers kill resistant patient-derived cells and control mouse tumors. The work identifies…

admin
October 1, 2026

Technology Modalities

MD Anderson Team Reports Dual MYC-GSPT1 Degrader for Blood Cancers

A peer-reviewed Blood study reports GT19630, a cereblon-dependent small-molecule degrader that directly recruits both MYC and GSPT1 and disrupts a newly described positive feedforward loop between the proteins. GT19630 produced low-nanomolar cytotoxicity across leukemia…

admin
August 18, 2026

ROR1 Emerges in Mantle-Cell Relapse After CD19 CAR-T

MD Anderson Team Reports Dual MYC-GSPT1 Degrader for Blood Cancers

Saturday Rounds